A detailed history of High Vista Strategies LLC transactions in Arcellx, Inc. stock. As of the latest transaction made, High Vista Strategies LLC holds 51,040 shares of ACLX stock, worth $4.22 Million. This represents 1.13% of its overall portfolio holdings.

Number of Shares
51,040
Previous 72,230 29.34%
Holding current value
$4.22 Million
Previous $5.02 Million 43.94%
% of portfolio
1.13%
Previous 1.98%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$49.74 - $66.98 $1.05 Million - $1.42 Million
-21,190 Reduced 29.34%
51,040 $2.82 Million
Q4 2023

Feb 14, 2024

SELL
$31.75 - $57.99 $184,086 - $336,226
-5,798 Reduced 7.43%
72,230 $4.01 Million
Q3 2023

Nov 14, 2023

BUY
$31.51 - $37.4 $477,660 - $566,946
15,159 Added 24.11%
78,028 $2.8 Million
Q2 2023

Aug 14, 2023

BUY
$27.49 - $46.9 $236,111 - $402,824
8,589 Added 15.82%
62,869 $1.99 Million
Q1 2023

May 15, 2023

BUY
$26.92 - $33.94 $1.46 Million - $1.84 Million
54,280 New
54,280 $1.67 Million

Others Institutions Holding ACLX

About Arcellx, Inc.


  • Ticker ACLX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,819,200
  • Market Cap $3.63B
  • Description
  • Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...
More about ACLX
Track This Portfolio

Track High Vista Strategies LLC Portfolio

Follow High Vista Strategies LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of High Vista Strategies LLC, based on Form 13F filings with the SEC.

News

Stay updated on High Vista Strategies LLC with notifications on news.